HOW TO PLAY AN ACTIVE ROLE IN YOUR CLL TREATMENT DECISIONS

Program Resource Guide

**MAKE YOUR VOICE HEARD. TAKE ACTION**
- Educate yourself about CLL.
- Include a friend or family member in your appointments.
- Consider a second opinion and/or a consult with a CLL specialist if you’re not being heard.

**CLL RESOURCES**
- CLL Society: cllsociety.org
- The Leukemia & Lymphoma Society: LLS.org
- Leukemia Research Foundation: allbloodcancers.org

**TARGETED CLL TREATMENTS**

**Approved Inhibitor Treatments for CLL**
- BTK inhibitors
  - Acalabrutinib (Calquence)
  - Ibrutinib (Imbruvica)
- PI3K inhibitors
  - Duvelisib (Copiktra)
  - Idelalisib (Zydelig)
- BCL-2 inhibitor
  - Venetoclax (Venclexta)

**Approved Monoclonal Antibody Treatments for CLL:**
- Alemtuzumab (Campath)
- Obinutuzumab (Gazyva)
- Ofatumumab (Arzerra)
- Rituximab (Rituxan)

**VISIT THESE RELATED PROGRAMS**
- Which CLL Treatment Approach Could be Right for You?
- Factors that Guide a CLL Treatment Decision
- Office Visit Planners for CLL Patients and Care Partners

**LEARN ABOUT CLINICAL TRIALS**
- Consult with a CLL specialist
- Visit The Leukemia & Lymphoma Society: LLS.org
- Visit Clinicaltrials.gov

**When Could It Be Time to Treat CLL? Indications Include:**
- Anemia and low platelets
- Bulky spleen or lymph nodes
- Disease progression and symptoms
**How to Play an Active Role in Your CLL Treatment Decisions**

Program Resource Guide

---

**Glossary of Terms**

- **Chimeric Antigen Receptor (CAR) T-cell therapy**: An immunotherapy that is currently being studied to treat CLL.
- **FCR**: A chemotherapy regimen that includes fludarabine, cyclophosphamide, and rituximab.
- **Fluorescent in situ hybridization (FISH)**: A chromosome test used to identify specific genes or chromosome changes.
- **Ibrutinib (Imbruvica)**: A BTK inhibitor CLL treatment.
- **IGHV Mutation**: CLL patients with mutated IGHV may have a longer time to treatment and can have different responses and duration of responses specific to chemotherapy.
- **MRD (minimal residual disease)**: Measurement of the levels of residual leukemia found in the bone marrow of patients in remission after a clinical response to treatment. MRD is important to determine risk stratification and treatment planning.
- **Obinutuzumab (Gazyva)**: A monoclonal antibody CLL treatment.
- **Watchful Waiting (or Active Surveillance)**: The period of time before treatment begins in which a patient is monitored for disease progression and symptoms.
- **17p Deletion**: A chromosome abnormality that can impact treatment response in CLL patients.

---

<table>
<thead>
<tr>
<th>Stages of CLL:</th>
<th>Who Is on Your CLL Team? Members Include:</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Stage 0: CLL cells are circulating in the body.</td>
<td>- An oncologist-hematologist</td>
</tr>
<tr>
<td>- Stage I: CLL cells accumulate in lymph nodes and cause swelling.</td>
<td>- Advanced practice provider, such as a nurse practitioner or a physician’s assistant</td>
</tr>
<tr>
<td>- Stage II: CLL cells accumulate in the spleen and cause an enlarged spleen.</td>
<td>- Pharmacists and pharmacy staff</td>
</tr>
<tr>
<td>- Stage III/IV: CLL cells accumulate in the bone marrow and cause anemia or thrombocytopenia.</td>
<td>- Family members and/or friends</td>
</tr>
<tr>
<td>- You!</td>
<td>- You!</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Treatment Considerations Include:</th>
<th>More Tools for Empowerment</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Risks, including side effects and their management.</td>
<td>- Digitally Empowered™</td>
</tr>
<tr>
<td>- Potential benefits, including the possibility and duration of remission.</td>
<td>- PEN Powered Activity Guide</td>
</tr>
<tr>
<td>- Other treatment options, if additional treatment is needed at a later time.</td>
<td>- Empowered Blog</td>
</tr>
<tr>
<td></td>
<td>- Empowered! Podcast</td>
</tr>
</tbody>
</table>